327 related articles for article (PubMed ID: 26876247)
1. [Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].
Jin L; Fu W; Xi H; Zhang C; Du J; He H; Jiang H; Zeng T; Fan J; Zhou L; Chang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):14-9. PubMed ID: 26876247
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and Influencing Factors of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Retrospective Analysis].
Zhang BL; Zhou J; Zhang GL; Gui RR; Lin QD; Zu YL; Yu FC; Zhao HF; Li Z; Wang J; Fu YW; Zhang LN; Zhou H; Fang BJ; Song YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1414-1419. PubMed ID: 30295260
[TBL] [Abstract][Full Text] [Related]
3. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
Kim H; Sohn HJ; Kim S; Kim K; Lee JH; Bang SM; Kim DH; Sohn SK; Lee JJ; Suh C
Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
5. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].
Sui WW; Zou DH; An G; Yi SH; Deng SH; Huang WY; Wang TY; Li J; Liu H; Fu MW; Lyu R; Liu W; Xu Y; Li ZJ; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):499-504. PubMed ID: 28655093
[No Abstract] [Full Text] [Related]
6. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
7. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
8. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
9. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
Wu Q; Liu JR; Huang BH; Zou WY; Gu JL; Chen ML; Kuang LF; Zheng D; Xu DR; Zhou ZH; Wang HH; Su C; Tong XZ; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):453-459. PubMed ID: 31340616
[No Abstract] [Full Text] [Related]
10. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
13. [Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma].
Zou DH; Sui WW; Yi SH; An G; Xu Y; Li ZJ; Li CW; Qi JY; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):299-303. PubMed ID: 23668200
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of Curative Efficacy of Different Chemotherapy Regimen Combined with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation on Multiple Myeloma].
Wang CB; Bai H; Xi R; Pan YZ; Wu T; Xu SF; Zhang Q; Zhou JM; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1675-1680. PubMed ID: 30501703
[TBL] [Abstract][Full Text] [Related]
17. [Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
Liang Z; Ren H; Cen X; Li Y; Wang L; Ou J; Dong Y; Yin Y; Wang W; Liu W; Wang Q; Qiu Z; Wang M; Xu W; Sun Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):225-30. PubMed ID: 24666489
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
19. Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
Lee BH; Shin SH; Min CK; Yhim HY; Kwak JY; Kim JA
Int J Hematol; 2013 May; 97(5):634-9. PubMed ID: 23605366
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
